Michael Keenan, page-7

So what if they hired him, they need whatever connections he can leverage for the companies growth - no place for that kind of ethics over here.

Also don't see any issue with the management and their growth here, for the product - the footprint growth has been fantastic. If you'll don't want to participate, then well and good.

It's been systematically expanding like it should, not an IT company that's going to see hyper growth, neither a biotech firm that's curing cancer, it's a biotech material company - market adopting the product has many many many challenges
and they have been clearly getting them knocked off one by one for a company that's been listed only since 2019 (right before the world took a breather for 2 years).

For people who don't have enough time to wait or money to risk it - pick another stock.